MCI DELIVERS: !. MOBILE, VIRTUAL, Sustainable B2B2C Medical Weight Loss for ADIPOSITY BASED CHRONIC DISEASE (ABCD) and Type 2 Diabetes REMISSION (T2D):
CVD, Heart Failure, Breast CA, HTN, CKD, PN, High Blood Pressure, and pre-transplant)
2: EXPANDING MCI’s SEMIAUTOMATED MVP to COMPLETE and Automate OUR 60% PMF for SALES in 3-4 months.
SELF-CONTAINED: 1-Stop Shopping
RAPID
SAFE
NON-STARVATION
NON-GLP-1 RECEPTOR AGONISTS
MODERATE WEIGHT REGAIN
META DATA and ANALYTICS
GUARANTEED RESULTS!
VALIDATED REAL TIME COST SAVINGS
MCI BLACK SWAN Deep Tech: 30N RCT + matched AI-ML Intensification of the MCI EXPERIENCE for Automation, Scalability, Improved outcomes, validated cost savings, Metadata, and Analytics,.
Patent pending AI-ML enabled PERSONAL CLINICAL and CBT LIBRARY MESSAGES
MCI Retrospective Semiautomated White Paper.
93 obese patients
Automated daily CBT podcasts and quizzes + high protein ketogenic diet.
Results: 73.1% (19/26N) T2D remission followed 9.79 months
Ozempic, et al vs MCI
MCI is a product that can break the GLP-1 monopoly and create a whole new market!
MCI Advantages over GLP-1’s:
Cost: MCI cost $4,664 pppy, includes meals, metadata, analytics, automated enrollment, and maintenance
GLP-1 : $1,000pppy. No data
Complications: GLP-1: High
MCI: minimal side effects!
Weight regain: GLP-1 high
: MCI moderate
Patent pending, AI-enabled CBT, personal clinical results, intuitive personal algorithm messages and reminders by Personal Virtual Assistant (PVA) for Neuroplasticity for safe, rapid, sustainable medical weight loss.
• 93N T2D
• 73.1% (19/26N) T2D Remission x 9.79 months
• 64% lost 10% or more weight
• 800 cal/d high protein ketogenic diet
Expand, FULLY Automate, and Massively scale to complete the remaining 50% of the Product Market Fit (PMF) to decrease staff burden and costs, and improve Quality of Care.
• Launch B2B2C sales $4664pp Y1 + Y2
• T2D cost = $20,000 pppy (CDC 2025)
• MCI estimated cost savings: $15,000
Samuel is a retired heart surgeon. He was an international Principal Investigator for FDA Phase III Trials for ATS Medical, Inc. (ATSI-Nasdaq). He founded University Medical Clinics Inc., a network of primary care clinics contracting with Medicare and HMOs. Samuel co-authored the company’s Daily Therapy© software and was the Investigator for the company’s virtual Phase I/II T2DM remission trials. He’s a graduate of Chicago Medical School.
John Hablak is an experienced and highly effective entrepreneur, having graduated University Colorado in operations management. In 2017 he co-founded and successfully operates the then largest medical marijuana clinic in South Florida. He has since separately acquired a major primary care medical clinic.
Jason is a US Navy veteran and liaison with the web technology and operations teams. He was a network development executive in the HMO industry and formerly COO of University Medical Clinics, Inc. He co-authored the company’s Daily Therapy© software and AI-based personal algorithms. Jason and Samuel co-designed the company’s patent-pending ecosystem.
Nick is acting COO and formerly Southeast US and Northern Caribbean Operations Director for St. Jude Medical and Medtronic. He was charged with contracting and purchasing with some of the country’s largest hospital systems. He is co-founder of Chelexa BioSciences, a patented technology to prevent MRSA, licensed to Hoth Therapeutics (NASDAQ). Nick is a Vietnam veteran serving as a Captain in the US Marine Corp.
For information, please contact Samuel Sadow, CEO, ssadow@mcihealth.com or 772 233-8183.